A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

BACKGROUND: The standard 6-month four-drug regimen for the treatment of drug-sensitive tuberculosis has remained unchanged for decades and is inadequate to control the epidemic. Shorter, simpler regimens are urgently needed to defeat what is now the world’s greatest infectious disease killer. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Patrick P. J., Dooley, Kelly E., Gillespie, Stephen H., Heinrich, Norbert, Stout, Jason E., Nahid, Payam, Diacon, Andreas H., Aarnoutse, Rob E., Kibiki, Gibson S., Boeree, Martin J., Hoelscher, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804526/
https://www.ncbi.nlm.nih.gov/pubmed/27004726
http://dx.doi.org/10.1186/s12916-016-0597-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804526/
https://www.ncbi.nlm.nih.gov/pubmed/27004726
http://dx.doi.org/10.1186/s12916-016-0597-3

Ejemplares similares